Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-7.04 Insider Own10.42% Shs Outstand1.38M Perf Week17.95%
Market Cap5.23M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.27M Perf Month-1.91%
Income-9.64M PEG- EPS next Q- Inst Own87.64% Short Float0.47% Perf Quarter-4.91%
Sales0.00M P/S- EPS this Y- Inst Trans-86.58% Short Ratio0.00 Perf Half Y-46.67%
Book/sh3.85 P/B0.96 EPS next Y- ROA-64.24% Short Interest0.01M Perf Year-61.11%
Cash/sh6.91 P/C0.53 EPS next 5Y- ROE-104.94% 52W Range2.95 - 16.11 Perf YTD-51.90%
Dividend Est.- P/FCF- EPS past 5Y70.75% ROI-181.40% 52W High-77.16% Beta0.63
Dividend TTM- Quick Ratio2.15 Sales past 5Y0.00% Gross Margin- 52W Low24.58% ATR (14)1.06
Dividend Ex-Date- Current Ratio2.15 EPS Y/Y TTM52.21% Oper. Margin0.00% RSI (14)48.21 Volatility41.96% 16.08%
Employees2 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price150.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-841.65% Payout- Rel Volume0.11 Prev Close3.90
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 15 AMC Avg Volume1.38M Price3.68
SMA200.24% SMA50-7.25% SMA200-40.13% Trades Volume146,248 Change-5.64%
Date Action Analyst Rating Change Price Target Change
May-24-21Initiated H.C. Wainwright Buy $25
Apr-13-21Initiated B. Riley Securities Buy $21
Mar-17-21Initiated ROTH Capital Buy $25
May-21-24 09:15AM
May-20-24 08:40AM
May-16-24 10:53AM
May-15-24 05:00PM
09:53PM Loading…
Mar-26-24 09:53PM
Feb-01-24 11:00AM
Dec-06-23 09:30AM
Dec-04-23 09:30AM
Nov-06-23 09:30AM
Nov-01-23 09:00AM
Aug-07-23 09:00AM
Aug-03-23 01:25PM
May-15-23 05:00PM
09:05AM Loading…
May-04-23 09:05AM
Apr-12-23 07:07AM
Mar-30-23 05:00PM
Feb-24-23 09:00AM
Feb-02-23 09:46AM
Dec-30-22 08:00AM
Dec-14-22 07:30AM
Dec-12-22 07:30AM
Nov-10-22 03:15PM
Nov-03-22 09:00AM
Oct-31-22 05:15PM
Oct-25-22 02:44PM
Oct-06-22 08:18AM
Oct-04-22 04:10PM
Sep-12-22 09:34AM
07:30AM Loading…
Sep-08-22 07:30AM
Aug-30-22 06:00PM
Aug-11-22 09:35AM
Jun-10-22 08:00AM
May-19-22 07:45AM
May-16-22 08:01AM
May-12-22 08:00AM
Apr-11-22 07:30AM
Mar-28-22 04:15PM
Mar-21-22 07:30AM
Mar-09-22 04:24PM
Mar-03-22 07:30AM
Feb-24-22 07:30AM
Feb-18-22 07:30AM
Jan-20-22 07:30AM
Jan-06-22 04:30PM
Jan-04-22 05:38PM
Dec-08-21 07:30AM
Nov-30-21 07:30AM
Nov-24-21 04:05PM
Nov-17-21 07:28AM
Nov-10-21 04:10PM
Nov-08-21 07:30AM
Oct-07-21 10:00AM
Sep-20-21 07:00AM
Sep-16-21 12:00PM
Sep-15-21 07:00AM
Sep-13-21 07:00AM
Sep-09-21 07:00AM
Sep-08-21 12:28PM
Aug-23-21 07:00AM
Aug-13-21 07:30AM
Aug-06-21 08:00AM
Aug-03-21 07:00AM
Jul-28-21 08:00AM
Jul-16-21 03:13AM
Jul-07-21 08:00AM
Jun-24-21 08:00AM
Jun-23-21 08:00AM
Jun-21-21 08:00AM
Jun-16-21 08:00AM
Jun-08-21 08:00AM
May-18-21 09:50AM
May-17-21 06:54PM
May-12-21 07:00AM
Apr-26-21 07:00AM
Apr-19-21 07:00AM
Apr-12-21 08:00AM
Apr-08-21 08:00AM
Mar-29-21 07:00AM
Mar-17-21 08:00AM
Mar-10-21 08:00AM
Mar-08-21 08:30AM
Mar-04-21 08:30AM
Mar-02-21 03:00AM
Feb-18-21 08:00AM
Feb-16-21 08:00AM
Feb-11-21 08:00AM
Jan-19-21 09:00AM
Jan-12-21 10:00AM
Jan-04-21 09:45AM
Dec-28-20 09:35AM
Dec-21-20 11:00AM
Dec-17-20 09:15AM
Dec-14-20 09:05AM
Dec-08-20 07:30AM
Nov-18-20 07:30AM
Nov-12-20 07:30AM
Oct-15-20 07:45AM
Oct-13-20 07:45AM
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.